Immunohistochemistry is a multi-step technique where each variable can affect the final result. When IHC fails — whether as weak staining, excessive background, or unexpected patterns — a systematic approach identifies the cause. Rigorous controls and optimization protocols minimize failures and ensure reliable diagnostic and predictive IHC.
Controls: The Foundation of IHC Quality
Every IHC run includes three essential controls. The positive control is a tissue known to express the target antigen at the expected intensity and subcellular localization (nuclear, cytoplasmic, or membranous). Ideally, the positive control is a tissue block processed identically to the test tissue — same fixative, same processing schedule, same block age. For predictive markers (ER, HER2, PD-L1), cell line controls with known expression levels are recommended.
The negative control is the same positive control tissue processed without primary antibody (or with non-immune immunoglobulin of the same species and concentration). Any staining in the negative control indicates non-specific binding of the detection system or endogenous enzyme activity.
The internal positive control is a non-neoplastic cell type within the test section that should express the target antigen. For example, lymphocytes serve as internal positive controls for CD45; endothelial cells for CD31; normal breast ducts for ER. Loss of the internal control suggests a technical failure rather than true antigen absence.
Weak or Absent Staining
Weak or absent staining when positive controls fail requires a systematic check. Starting from the beginning of the protocol: tissue fixation — over-fixation (>72 hours) can irreversibly mask antigens; under-fixation (<4 hours) allows antigen diffusion. Retrieve archived blocks with known positive results to distinguish fixation from processing problems. Antigen retrieval — increase HIER time or temperature, switch to a higher-pH buffer (Tris-EDTA pH 9.0 instead of citrate pH 6.0), or try enzymatic retrieval. Antibody — verify the antibody is not expired, has not been subjected to freeze-thaw cycles, and is at the correct dilution. Titrate the primary antibody in serial dilutions (1:50, 1:100, 1:200, 1:400) to find optimal concentration. Detection system — check that secondary antibody matches the primary species; verify chromogen (DAB) is fresh and hydrogen peroxide has not degraded.
Excessive Background
Background staining obscures specific signal and can lead to false interpretation. Endogenous peroxidase activity (in RBCs, neutrophils) is blocked by pre-treatment with 3% hydrogen peroxide for 10-15 minutes. Endogenous biotin in liver, kidney, and brain tissues causes background with avidin-biotin detection systems — switch to polymer-based detection to avoid this. Primary antibody concentration too high — titrate down until background resolves while specific signal is retained. Incubation time or temperature too high — reduce primary antibody incubation from 60 minutes to 30 minutes at room temperature, or from overnight at 4°C to 60 minutes. Insufficient washing — increase wash buffer volume, number of washes, and wash time (minimum 3 x 5 minutes in PBS or TBS). Dried sections — if the tissue section dries at any step, antibodies bind non-specifically; ensure sections remain covered with reagent throughout.
False-Positive and False-Negative Results
A false-positive result (staining where antigen is absent) can occur from antibody cross-reactivity — the antibody recognizes a different protein with a similar epitope. Check the antibody datasheet for known cross-reactivities and confirm with a different antibody clone. Edge artifact (staining at tissue edges) results from drying or uneven section adherence — ensure complete coverage and proper section mounting.
A false-negative result (no staining where antigen is present) most often results from inadequate antigen retrieval for the specific fixation conditions. Antigen degradation in old blocks or sections cut long before staining requires stronger retrieval or use of freshly cut sections. Primary antibody not recognized by the detection system — verify species specificity of secondary antibody.
Optimization Protocol for New Antibodies
When introducing a new antibody, perform a titer matrix testing four primary antibody dilutions against four retrieval conditions (citrate pH 6.0 HIER, Tris-EDTA pH 9.0 HIER, proteinase K, no retrieval) on a known positive control tissue. Score each combination for intensity (0-3+), percentage of positive cells, and background (0-3+). Select the dilution-retrieval combination that gives the strongest specific signal with minimal background. Document the optimized protocol and include it in the laboratory’s quality assurance records.
Automated IHC Validation
Automated IHC platforms (Ventana, Dako, Leica) improve reproducibility but require protocol validation when transitioning from manual methods. Run the same validation set (minimum 10 positive and 10 negative cases) on both the manual and automated platform. Compare intensity, percentage, localization, and background. A 90% concordance threshold is typically required for clinical validation.
